The mRNA Drug Discovery and Manufacturing Platforms Market will expand from USD 0.47 billion in 2026 to USD 0.81 billion in 2031, at an 11.3% CAGR.
The modern biopharmaceutical industry is undergoing significant change due to the introduction of mRNA-based drug discovery and manufacturing platforms, which provide rapid design, optimization and high-volume production capabilities for RNA-derived therapeutics. These platforms combine multiple components required to develop RNA-derived therapeutics (e.g., sequence design, in vitro transcription, purification, formulation and delivery system development). Unlike traditional drug development, mRNA-based drug development allows for modifications (both large and small) of the genetic sequence by scientists, reducing the amount of time required to complete the development process and increasing the flexibility of multiple therapeutic areas. It is anticipated that mRNA-based drug discovery and manufacturing platforms will be significantly utilised to develop vaccines, cancer immunotherapies, protein replacement therapies and treatments for rare genetic disorders. It is expected that advances in lipid nanoparticle (LNP) delivery systems and stabilization techniques will significantly enhance the safety, efficacy and stability of mRNA-derived products, thus addressing previous challenges associated with the degradation and targeted delivery of mRNA-derived products. Additionally, current mRNA development and manufacturing platforms incorporate the use of artificial intelligence (AI) and bioinformatics tools to improve sequence optimization and predictive modeling for improved overall success rates in drug development. The market for RNA-derived products is also experiencing increased support from pharmaceutical companies and contract development and manufacturing organizations through growing partnerships and collaborations between biotechnology companies, pharmaceutical companies and contract development and manufacturing organizations. Such partnerships facilitate scalability, compliance with regulatory requirements and enable the new product to be commercialized more quickly than would otherwise be possible. As the availability of RNA-derived therapeutics continues to grow, mRNA drug discovery and manufacturing platforms will become a fundamental part of the global infrastructure of next-generation drug discovery and manufacturing strategies.
Increasing Need for Fast Drug Development: mRNA platforms allow for faster development of drugs when compared to traditional methods of drug development. This capability is extremely important when it comes to diseases that are rapidly emerging and accelerating clinical pipelines. Pharmaceutical companies are adopting these platforms to decrease time-to-market and improve their ability to be flexible when responding to changes in global healthcare needs.
Improvements in mRNA Manufacturing Technologies: Through the use of improved technology in synthesising mRNA from in vitro transcription, purification, and lipid nanoparticles, mRNA therapeutics can now be produced on an industrial scale, decreasing the costs associated with producing a drug. Continuous improvement in science will allow for better production yield and production costs, allowing commercialisation of RNA products across multiple therapeutic indications.
Increased Investment & Strategic Partnerships: Biotech firms, government agencies, and investors have made large investments in the infrastructure to support mRNA research. By building strategic partnerships with CDMOs, biotech firms are able to expand their drug discovery and production abilities. These partnerships will significantly enhance the number of innovative drugs that can go through clinical development, and increase the drug development timelines for these innovative drugs.
Expanding Applications in Oncology and Rare Diseases: mRNA platforms are increasingly used in cancer immunotherapy and genetic disorder treatments. Their ability to target specific proteins and pathways enables personalized therapies. Growing clinical success and pipeline expansion in oncology and rare diseases are driving demand for advanced mRNA drug discovery and manufacturing platforms globally.
The market faces challenges such as high production costs, cold-chain requirements, and regulatory complexities. Supply chain limitations for key raw materials also impact scalability. However, opportunities lie in AI-driven platform development, decentralised manufacturing, and expansion into personalised medicine. Increasing clinical success and technological advancements are expected to drive long-term growth.
June 2025: In 2025, BioNTech strengthened its position in RNA therapeutics by acquiring CureVac, significantly expanding its mRNA technology capabilities, intellectual property portfolio, and manufacturing capacity. This strategic move enhances BioNTech’s development of next-generation mRNA-based cancer immunotherapies and reinforces industry consolidation in RNA platonic.
The market is segmented by product type, RNA type, application and geography.
The mRNA manufacturing platform is one of the crucial segments used to develop high-quality mRNA based therapeutics and vaccines at scale. The platform consists of in vitro transcription, purification, and formulation processes that allow for the production of an effective and stable final product. Manufacturer adoption of the mRNA manufacturing platform continues to increase as a result of the growing need for large-scale production in compliance with Good Manufacturing Practices (GMP). Ongoing improvements in the areas of automation, yield optimisation, and cost efficiencies improve the ability of mRNA manufacturers to rapidly commercialise and distribute mRNA-based products globally.
Oncology is one of the primary applications of mRNA platforms, which are being used to create individualised cancer therapies (personalised medicine) and immunotherapy to treat cancer. mRNA platforms are being utilised to develop cancer vaccines created to stimulate the immune system against tumour-specific antigens. The number of clinical trials for targeted mRNA products is increasing, in addition to advancements in mRNA technologies for targeted cancer therapies, resulting in an increased rate of adoption of mRNA oncology products by 2025. The transition towards using precision medicine, in conjunction with the growing number of patients with cancer, will result in high demand for mRNA-based solutions in oncology.
Lipid nanoparticle (LNP) formulations are one of the leading technologies to deliver mRNA into cells safely and effectively. LNPs protect mRNA from degradation and ensure that it is delivered to the intended target. The ongoing improvements being made to LNP designs will make the mRNA therapeutics and vaccines more stable, less toxic, and more efficient to deliver by 2025. As such, LNP technology will play a critical role in the success of mRNA-based therapeutics and vaccines and will serve as a key foundation for the development of mRNA platforms.
Development of innovative mRNA therapeutics through collaboration with leading biotechnology companies and academic institutions, as well as support from governments (national and state) through regulations and funding programs, is helping to support growth in North America. The region will benefit from an increasing number of clinical trials, a growing pipeline of oncology and rare disease therapeutics, and continued technological advances in the design and manufacture of mRNA products to support the use of mRNA-based therapies in the treatment of patients with COVID-19, cancer and other diseases.
South America is experiencing moderate growth as countries gradually invest in biotechnology and pharmaceutical manufacturing capabilities. Brazil and Argentina are leading adoption with increasing research initiatives and collaborations with global biotech firms. In 2025, demand for advanced therapeutics and vaccines is encouraging investment in mRNA platforms. However, limited infrastructure and funding constraints may slow widespread adoption. Governments are focusing on improving healthcare systems and expanding local production capabilities. Partnerships with international organizations and technology providers are expected to support knowledge transfer and capacity building, contributing to steady long-term growth in the region.
Europe is also a significant contributor to the growth of the mRNA platforms market, due to strong government support and investment in biotechnology and life sciences, along with a focus on creating local manufacturing capabilities for mRNA-based products. For example, Germany, the UK and France are working collectively to build local facilities in order to ensure that Europe has a resilient healthcare system in response to future global health challenges.
Middle East & Africa are both beginning to show signs of transitional growth within mRNA drug development and manufacturing growth due to an increase in investment within the biotechnology and healthcare sectors. The Middle East, however, the UAE and Saudi Arabia will continue to develop their advanced pharmaceutical manufacturing capacity. Key partnerships with major international biopharmaceutical companies would greatly improve infrastructure development in the region. In Africa, mRNA patterns are slower to develop; however, there is improvement through international partner projects and funding. As more people gain access to knowledge regarding advanced therapeutics, there will be more growth in healthcare systems and local produce, which should drive gradual regional market growth throughout the region.
The Asia-Pacific region is expected to experience the highest growth rate through 2025 for several reasons, including increasing investment in biopharmaceutical manufacturing capacity across the region; countries such as China, India, Japan and South Korea have prioritized investing in the infrastructure necessary to develop mRNA platforms and build their own mRNA drug development and manufacturing capabilities. In addition, private industry investments in the from- and industry partnerships are expected to accelerate this level of innovation and manufacturing as well as support collaboration with government funding of programs focused on the advancement of the mRNA sector.
Moderna
BioNTech
CureVac
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Ionis Pharmaceuticals
Translate Bio
GSK
Sanofi
Arcturus Therapeutics
BioNTech is a global biotechnology company that develops and commercialises new mRNA-based therapeutics and immunotherapies. The company gained worldwide visibility as a result of its partnership with Pfizer to develop the mobile RNA vaccine for COVID-19. BioNTech plans to develop additional personalised cancer vaccines that use mRNA to stimulate the patient's own immune system to attack their own tumours. The company has dedicated significant investments to developing next-generation mRNA platform technologies, including cell-based therapies and artificial intelligence-derived drug candidates. Its robust pipeline of oncology-related products will greatly assist in driving future growth.
Alnylam Pharmaceuticals has established itself as a pioneer in the development and commercialization of RNA interference (RNAi) therapies utilising small interfering RNAs (siRNAs). The company's initial focus has been on developing therapies for rare and/or genetic diseases, and through its commercial introduction of multiple siRNA-based therapies, Alnylam is currently the leader in the siRNA-based therapeutic market. In 2025, Alnylam has committed itself to expanding its pipeline in the treatment of patients with cardiometabolic, hepatic and/or neurological diseases. In addition, Alnylam has invested a significant amount of resources in the development of proprietary technologies that enhance the ability to target a specific gene in order to enhance therapeutic outcomes. Alnylam is well-positioned for significant growth and innovation through its extensive clinical portfolio, regulatory approvals, and strategic partnerships with world-class pharmaceutical companies relating to RNA-based therapeutics, particularly in the areas of precision medicine and the treatment of rare diseases.
Moderna is one of the leading biopharmaceutical companies developing therapeutic and preventive medications using messenger RNA (mRNA) technologies. The company's global presence has grown significantly since being recognized for its COVID-19 vaccine; however, the expansion of its product line now also includes products in oncology, rare disease and respiratory indications. In 2025, the development of mRNA-based personalised cancer vaccines will continue, as well as further research into the co-administration of mRNA-based therapeutic agents and advances in the use of lipid nanoparticles as mRNA delivery systems. Moderna's vast research and development capacity, substantial manufacturing capabilities and significant partnerships effectively place it among the leading RNA therapeutic companies in the world.
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 0.47 billion |
| Total Market Size in 2031 | USD 0.81 billion |
| Forecast Unit | Billion |
| Growth Rate | 11.3% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |